金属硫蛋白在代谢性疾病中的研究进展

doi:10.16352/j.issn.1001-6325.2022.03.019

基础医学与临床 ›› 2022, Vol. 42 ›› Issue (3): 498-501.doi: 10.16352/j.issn.1001-6325.2022.03.019

金属硫蛋白在代谢性疾病中的研究进展

杨燕^*

兰州大学第二医院内分泌科, 甘肃兰州 730030

收稿日期:2020-11-13 修回日期:2021-04-06 出版日期:2022-03-05 发布日期:2022-03-04
通讯作者: ^* yanzi2004099@sina.com
基金资助:
国家自然科学基金(81960165);甘肃省卫生行业科研计划项目(GSWSKY2018-35);兰大二院“萃英科技创新”计划(CY2018-MS01)

Research progress of metallothionein in metabolic diseases

YANG Yan^*

Department of Endocrinology, the Second Hospital of Lanzhou University, Lanzhou 730030, China

Received:2020-11-13 Revised:2021-04-06 Online:2022-03-05 Published:2022-03-04
Contact: ^* yanzi2004099@sina.com

摘要/Abstract

摘要： 金属硫蛋白(MT)是一类富含半胱氨酸的低分子金属结合蛋白,主要通过抗氧化应激、抗感染、抑制细胞凋亡机制,对肥胖症、非酒精性脂肪肝病(NAFLD)和糖尿病(DM)及并发症起到保护作用。

关键词: 金属硫蛋白, 代谢性疾病, 进展

Abstract: Metallothionein (MT) is a kind of low molecular metal binding proteins rich in cysteine. It plays a protective role in obesity, non-alcoholic fatty liver disease (NAFLD), diabetes mellitus(DM) and its complications. It has many functions such as anti-oxidative stress, anti-inflammatory, and inhibiting cell apoptosis.

Key words: metallothionein, metabolic disease, progress

中图分类号:

杨燕. 金属硫蛋白在代谢性疾病中的研究进展[J]. 基础医学与临床, 2022, 42(3): 498-501.

YANG Yan. Research progress of metallothionein in metabolic diseases[J]. Basic & Clinical Medicine, 2022, 42(3): 498-501.

参考文献

[1]Sato M, Kawakami T, Kadota Y, et al. Obesity and metallothionein [J]. Curr Pharm Biotechnol, 2013,14:432-440.
[2]Butler MG, Wang K, Marshall JD, et al. Coding and noncoding expression patterns associated with rare obesity-related disorders: Prader-Willi and Alström syndromes [J]. Adv Genomics Genet, 2015,2015:53-75.
[3]Kawakami T, Takasaki S, Kadota Y, et al. Regulatory role of metallothionein-1/2 on development of sex differences in a high-fat diet-induced obesity [J]. Life Sci, 2019,226:12-21.
[4]Lindeque JZ, Jansen van Rensburg PJ, Louw R, et al. Obesity and metabolomics: metallothioneins protect against high-fat diet-induced consequences in metallothionein knockout mice [J]. OMICS, 2015,19:92-103.
[5]Byun HR, Kim DK, Koh JY. Obesity and downregulated hypothalamic leptin receptors in male metallothionein-3-null mice [J]. Neurobiol Dis, 2011,44:125-132.
[6]Kadota Y, Toriuchi Y, Aki Y, et al. Metallothioneins regulate the adipogenic differentiation of 3T3-L1 cells via the insulin signaling pathway [J]. PLoS One, 2017,12:e0176070. doi: 10.1371/journal.pone.0176070.
[7]Wang S, Gu J, Xu Z, et al. Zinc rescues obesity-induced cardiac hypertrophy via stimulating metallothionein to suppress oxidative stress-activated BCL10/CARD9/p38 MAPK pathway [J]. J Cell Mol Med, 2017,21:1182-1192.
[8]Song M, Vos MB, McClain CJ. Copper-fructose interactions: a novel mechanism in the pathogenesis of NAFLD [J]. Nutrients, 2018,10:1815.
[9]Hwang S, He Y, Xiang X, et al. Interleukin-22 ameliorates neutrophil-driven nonalcoholic steatohepatitis through multiple targets [J]. Hepatology, 2020,72:412-429.
[10]Ackerman Z, Skarzinski G, Grozovski M, et al. Effects of antihypertensive and triglyceride-lowering agents on hepatic copper concentrations in rats with fatty liver disease [J]. Basic Clin Pharmacol Toxicol, 2014,115:545-551.
[11]Liang T, Zhang Q, Sun W, et al. Zinc treatment prevents type 1 diabetes-induced hepatic oxidative damage, endoplasmic reticulum stress, and cell death, and even prevents possible steatohepatitis in the OVE26 mouse model: Important role of metallothionein [J]. Toxicol Lett, 2015,233:114-124.
[12]Sekovanić A, Jurasović J, Piasek M. Metallothionein 2A gene polymorphisms in relation to diseases and trace element levels in humans [J]. Arh Hig Rada Toksikol, 2020,71:27-47.
[13]Park Y, Zhang J, Cai L. Reappraisal of metallothionein: Clinical implications for patients with diabetes mellitus [J]. J Diabetes, 2018,10:213-231.
[14]Giacconi R, Cai L, Costarelli L, et al. Implications of impaired zinc homeostasis in diabetic cardiomyopathy and nephropathy [J]. Biofactors, 2017,43:770-784.
[15]Raudenska M, Dvorakova V, Pacal L, et al. Levels of heavy metals and their binding protein metallothionein in type 2 diabetics with kidney disease [J]. J Biochem Mol Toxicol, 2017,31. doi: 10.1002/jbt.21891.
[16]Park L, Min D, Kim H, et al. The combination of metallothionein and superoxide dismutase protects pancreatic β cells from oxidative damage [J]. Diabetes Metab Res Rev, 2011,27:802-808.
[17]Chen S, Han J, Liu Y. Dual opposing roles of metallothionein overexpression in C57BL/6J mouse pancreatic β-cells [J]. PLoS One, 2015,10:e0137583. doi: 10.1371/journal.pone.0137583.
[18]Bensellam M, Shi YC, Chan JY, et al. Metallothionein 1 negatively regulates glucose-stimulated insulin secretion and is differentially expressed in conditions of beta cell compensation and failure in mice and humans [J]. Diabetologia, 2019,62:2273-2286.

金属硫蛋白在代谢性疾病中的研究进展

Research progress of metallothionein in metabolic diseases

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	苏鹏飞, 蒋林, 章盈婧, 郭博, 马志强, 周炜洵, 于健春. 综合治疗79岁进展期胃癌1例[J]. 基础医学与临床, 2021, 41(7): 1043-1046.
[2]	周杰, 黄英辉. 核转位在肿瘤发生发展中的研究进展[J]. 基础医学与临床, 2020, 40(8): 1119-1123.
[3]	周永婷, 叶菜英, 朱蕾. NLRP3炎性小体激活调控机制及抑制剂研究新进展[J]. 基础医学与临床, 2020, 40(8): 1113-1118.
[4]	张静, 王肖枭, 周怡, 王雪, 顾开明, 叶迎春. 肠道菌群与疾病相关性的研究进展[J]. 基础医学与临床, 2020, 40(2): 243-247.
[5]	何芳秦青青郑永钦贺军栋. miR-338在肿瘤中的研究进展[J]. 基础医学与临床, 2018, 38(6): 840-844.
[6]	顾胜龙赵蕊应苗法李明星. 曲妥珠单抗对肿瘤靶向治疗的研究进展[J]. 基础医学与临床, 2018, 38(5): 722-726.
[7]	庞新岗李永刚包倪荣丛宇. 骨代谢主要信号通路及信号分子的研究进展[J]. 基础医学与临床, 2018, 38(12): 1799-1803.
[8]	惠敏刘小海王任直. 儿童库欣病研究进展[J]. 基础医学与临床, 2018, 38(10): 1452-1456.
[9]	崔宁李蕾崔鸣兰峰. 人诱导性多潜能干细胞建立心肌细胞疾病模型的研究进展[J]. 基础医学与临床, 2017, 37(9): 1331-1335.
[10]	陈志刚岳红丽赵岩韩如泉. 脊柱脊髓手术围术期镇痛管理进展[J]. 基础医学与临床, 2017, 37(4): 571-575.
[11]	吴兴成严维刚. MicroRNAs在前列腺癌中的研究进展[J]. 基础医学与临床, 2016, 36(2): 281-284.
[12]	肖忠华苗加伟. 恶性肿瘤外泌体蛋白质组学研究进展[J]. 基础医学与临床, 2015, 35(10): 1406-1409.
[13]	王蒙蒙刘卓琦王晟范瑞琦杨晓红罗达亚. miRNA-205调控靶基因的研究进展与趋势[J]. 基础医学与临床, 2015, 35(1): 112-116.
[14]	左晖沈悦海郭晓汐王冠林张宽仁. 系统生物学指导下基于TRAIL网络靶向抗肿瘤研究进展[J]. 基础医学与临床, 2015, 35(1): 122-125.
[15]	何金花黎毓光. 长链非编码RNA与病毒和微小非编码RNA关系的研究进展[J]. 基础医学与临床, 2013, 33(7): 923-926.